- Meeting abstract
- Open Access
MRgFUS for Uterine Myomas: Safety, Effectiveness and Pathogenesis
© Kurashvili et al; licensee BioMed Central Ltd. 2014
- Published: 10 December 2014
- Connective Tissue
- Contrast Enhancement
- Symptom Score
- Benign Tumor
- Volume Reduction
Myomas are common benign tumors in woman. Patients prefer non-invasive treatment to preserve fertility and avoid surgery. In 2004 FDA approved MRgFUS for uterine myoma. The current study examined the safety and efficacy of MRgFUS for different myomas characteristics. Methods and Materials: A total of 925 patients, aged 20-55, with symptomatic myomas underwent MRgFUS (2006-2012). Prior to the treatment patients underwent gynecological examinations, MRI, biopsy. Safety was determined by tracking adverse events. Efficacy was assessed by measurement of NPV. MRI with contrast enhancement, symptom scores, treatments durability were also used as efficacy measures.
There was a low rate of complications (0.6%). MRgFUS resulted in volume reduction, symptomatic improvement, increase in the QoL, reduction in the vascularity, and long-term durability (4.5-5 years). A durability of symptoms improvement correlated with an NPV. MRgFUS was more effective for patients with less than 3 myomas unobstructed, myomas characterized by MR-hypo-intensity, a diameter of 2 to 6-8 cm, and an intramural component greater than 30%. Hypo-intense myomas are optimal candidates because the abundant connective tissue absorbs the FUS energy. Mitotically active and edematous myomas are not ideal due to limited connective tissue and the absence of a substratum for FUS absorption, respectively.
MRgFUS is a safe method of symptomatic treatment, effective in prevention of clinical symptoms, preparation for transcervical myomectomy, delay of surgery.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.